BROADCASTS.com

Chas Bountra is a professor of translational medicine at the University of Oxford as well as Chief Scientist at the Structural Genomic Consortium, a public-private partnership that supports the discovery of new medicines through open access research. Prior to coming back to Oxford, Chas spent many years in the pharmaceutical industry and culminated as Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron).